This film just can't get a break. It's almost like... cursed or something.
NYS Entity Status
NYS Filing Date
JANUARY 14, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - BULLDOZER MANAGEMENT LTD.
Around the Web
- ‘Amityville: The Awakening’ Is Finally Being Released… For Free
By Caleb Reading - Friday Sep 22, 2017
- Alibaba Co-Founder Joseph Tsai Said to Buy Brooklyn Nets Stake
By MICHAEL J. de la MERCED and JOE DRAPE - Friday Oct 27, 2017
Mr. Tsai has agreed in principle to buy a 49 percent stake in the team, people briefed on the matter said, valuing the franchise at $2.3 billion.
- Citigroup, 21st Century Fox, Twitter: Prince’s Arrest Touches Many
By ALEXANDRA STEVENSON - Sunday Nov 5, 2017
Prince Alwaleed’s arrest is likely to reverberate across dozens of publicly listed companies that count him as a major investor.
- Weinstein Company’s ‘Amityville’ Fizzles While ‘The Square’ Soars at Indie Box Office
By Jeremy Fuster, provided by
- Sunday Oct 29, 2017
This week’s indie box office results were a case of extremes, as “Amityville: The Awakening” — the latest from the scandal-riddled Weinstein Company — made less than $1,000 total in its limited release, while this year’s Palme D’Or winner, “The Square,” had a stellar four-screen opening with $76,000 and a $19,000 per screen average.“Amityville,” which is being released by The Weinstein Company through Dimension Films, made a mere $742 for a per screen average of $74 from 10 screens.
- Samsung Electronics CEO Kwon Oh-hyun to step down in March 2018
By Reuters - Friday Oct 13, 2017
(Reuters) — Samsung Electronics Co Ltd said on Friday its CEO and Vice Chairman Kwon Oh-hyun had decided to step down from management, as it forecast record third-quarter profits on the back of soaring memory chip prices. The surprise resignation comes as Kwon was expected to take a bigger role following the arrest of Samsung […]
- Take the Generic, Patients Are Told. Until They Are Not.
By CHARLES ORNSTEIN and KATIE THOMAS - Sunday Aug 6, 2017
Consumers have grown used to being told to give up their brand-name drugs in favor of cheaper generics. Now some are finding the opposite is true.